ストックスクリーナーアプリを入手
101.87
2.16%
2.15
アフターアワーズ：
101.26
-0.61
-0.60%
前日終値:
$99.72
開ける：
$99.3
24時間の取引高:
1.17M
Relative Volume:
1.18
時価総額：
$24.42B
収益：
$3.30B
当期純損益:
$-501.07M
株価収益率:
8.8288
EPS:
11.5384
ネットキャッシュフロー:
$1.03B
1週間 パフォーマンス:
-6.31%
1か月 パフォーマンス:
-8.86%
6か月 パフォーマンス:
+12.43%
1年 パフォーマンス:
+2.50%
1日の値動き範囲:
$98.25
$102.48
1週間の範囲:
$94.31
$115.93
52週間の値動き範囲:
$76.53
$131.49
Biontech Se Adr Stock (BNTX) Company Profile
BNTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-09-24 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | アップグレード | Jefferies | Hold → Buy |
| 2024-09-16 | アップグレード | JP Morgan | Underweight → Neutral |
| 2024-08-07 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-08-02 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-05-14 | 開始されました | Evercore ISI | In-line |
| 2024-02-23 | 開始されました | BMO Capital Markets | Outperform |
| 2024-01-05 | 開始されました | Oppenheimer | Perform |
| 2023-12-01 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-10-16 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-17 | アップグレード | Redburn | Neutral → Buy |
| 2022-12-15 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-08-17 | 開始されました | Cowen | Market Perform |
| 2022-07-13 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | 再開されました | Canaccord Genuity | Buy |
| 2022-02-01 | アップグレード | Redburn | Sell → Neutral |
| 2021-12-16 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-11-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | 開始されました | Deutsche Bank | Hold |
| 2021-10-07 | 開始されました | Jefferies | Hold |
| 2021-08-11 | アップグレード | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-06-16 | ダウングレード | Redburn | Neutral → Sell |
| 2021-05-18 | 開始されました | Goldman | Neutral |
| 2021-05-11 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-08-03 | 再開されました | Berenberg | Buy |
| 2020-07-21 | アップグレード | BofA Securities | Neutral → Buy |
| 2020-06-30 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-03-09 | 開始されました | H.C. Wainwright | Neutral |
| 2020-01-24 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | ダウングレード | UBS | Buy → Neutral |
| 2019-11-05 | 開始されました | Wolfe Research | Outperform |
| 2019-11-04 | 開始されました | Berenberg | Buy |
| 2019-11-04 | 開始されました | BofA/Merrill | Buy |
| 2019-11-04 | 開始されました | Canaccord Genuity | Buy |
| 2019-11-04 | 開始されました | JP Morgan | Overweight |
| 2019-11-04 | 開始されました | SVB Leerink | Outperform |
| 2019-11-04 | 開始されました | UBS | Buy |
すべてを表示
Biontech Se Adr (BNTX) 最新ニュース
BioNTech SE ADR (BNTX): An Important Analyst Insights - Stocks Register
Powell Speaks The Truth - Benzinga
Goodwin, Conyers, A&O Shearman Act on $800M China Biotech Sale - Law.com International
BioNTech ADR Clears Technical Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily
BioNTech SE ADR rises Wednesday, outperforms market - MarketWatch
BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition - Benzinga
BioNTech SE ADR falls Tuesday, underperforms market - MarketWatch
BioNTech SE ADR falls Monday, underperforms market - MarketWatch
BioNTech SE ADR rises Friday, outperforms market - MarketWatch
BioNTech SE ADR falls Wednesday, underperforms market - MarketWatch
BioNTech SE ADR rises Tuesday, outperforms market - MarketWatch
BioNTech SE Reports Strong Q3 2024 Results - TipRanks
This 6%-yielding U.S. pharma giant is a safe hold - The Globe and Mail
BioNTech SE ADR falls Friday, underperforms market - MarketWatch
BioNTech SE ADR outperforms market despite losses on the day - MarketWatch
Will Non-COVID Drugs Again Boost Pfizer's Top Line in Q3 Earnings? - Nasdaq
BioNTech to Report Q3 Earnings: Is a Beat in the Cards? - MSN
BioNTech SE ADR rises Thursday, outperforms market - MarketWatch
BioNTech's mRNA Technology and Acquired Oncology Programs Could Support a Future Moat - Morningstar
BioNTech SE ADR rises Wednesday, still underperforms market - MarketWatch
A better buy-in window may exist right now for BioNTech SE ADR (BNTX) - SETE News
Insider’s View: Deciphering BioNTech SE ADR (BNTX)’s Financial Health Through Ratios - The Dwinnex
BioNTech SE ADR (BNTX)’s stock decline to 121.55 per share - US Post News
BioNTech SE ADR falls Monday, still outperforms market - MarketWatch
What is BioNTech SE ADR (BNTX) Stock Return on Shareholders’ Capital? - SETE News
BioNTech SE ADR (BNTX)’s results reveal risk - US Post News
Gaining Ground: BioNTech SE ADR (BNTX) Closes Higher at 119.93, Up 0.98 - The Dwinnex
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty - Yahoo Finance
BioNTech unveils AI advancements in immunotherapy - Investing.com
BioNTech SE ADR rises Monday, outperforms market - MarketWatch
BioNTech SE ADR (BNTX) can make a big difference with a little luck - SETE News
Wall Street SWOT: BioNTech stock shows promise amid oncology pipeline growth - Investing.com
Are Smart Investors Making the Right Decision? BioNTech SE ADR (BNTX) - SETE News
What Are You Thinking About Investing In BioNTech SE ADR (NASDAQ: BNTX) Stock? - Stocks Register
Biontech Se Adr (BNTX) 財務データ
収益
当期純利益
現金流量
EPS
0.81%
7.22%
大文字化:
|
ボリューム (24 時間):